ANNEXON, INC. Cash and Restricted Cash
ANNEXON, INC. (ANNX) had Cash and Restricted Cash of $200.30 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $200.30M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $176.24M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $163.08M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $140.45M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $200.30M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $176.24M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $163.08M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $140.45M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $133.32M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $98.15M 10-Q · filed 2026-05-07 | |
| 2024-12-31 | $50.53M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $80.57M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $158.34M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $152.97M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $226.14M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $134.19M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $114.65M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $145.15M 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $141.05M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $211.69M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $105.65M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $113.99M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $76.01M 10-K · filed 2024-03-26 | |
| 2021-09-30 | $69.69M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $100.75M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $207.81M 10-Q · filed 2022-05-09 | $207.84M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $268.56M 10-K · filed 2023-03-06 | |
| 2020-09-30 | $370.69M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $124.76M 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $33.35M 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $43.93M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |